Drug intelligence / Profile preview

OK1

Development stage: Phase 2
Lead developer: POLYSAN
Modality: Small Molecules
Administration: Oral

Overview

OK1 is a drug candidate currently in the pharmaceutical development stage, being developed by the Russian pharmaceutical company POLYSAN. As of the latest pipeline updates, the company has not disclosed the specific therapeutic indication, molecular target, or mechanism of action for this asset. POLYSAN's research focus typically includes immunomodulators, antioxidants, and neuroprotective agents, but the specific classification of OK1 remains proprietary. The pharmaceutical development phase typically encompasses preclinical research, including substance synthesis and formulation optimization.

Targets

HSPA5 (Heat shock protein family A member 5)HSPA9 (Heat shock protein family A member 9)HSPA8 (Heat shock cognate 71 kDa protein)

Beyond the preview

Go deeper on OK1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OK1.

Explore the full profile